Last reviewed · How we verify
Placebo for Hydrochlorothiazide
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no pharmacological effect. Used for Control arm in Phase 3 clinical trial for hydrochlorothiazide efficacy.
At a glance
| Generic name | Placebo for Hydrochlorothiazide |
|---|---|
| Sponsor | IlDong Pharmaceutical Co Ltd |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. It relies on the placebo effect—psychological and physiological responses to the expectation of treatment—rather than any direct molecular mechanism. In this context, it serves as the control arm in a Phase 3 trial comparing the effects of hydrochlorothiazide against no active treatment.
Approved indications
- Control arm in Phase 3 clinical trial for hydrochlorothiazide efficacy
Common side effects
Key clinical trials
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life (PHASE3)
- Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction (EARLY_PHASE1)
- Study to Evaluate the Influence of Hydrochlorothiazide on Dermal Photosensitivity and DNA Stability - a Pilot Study (HCTox Study) (PHASE1)
- Candesartan Cilexetil + Chlorthalidone + Amlodipine Versus Exforge HCT®️ for Systemic Arterial Hypertension (PHASE3)
- Mitigating the Pro-inflammatory Phenotype of Obesity (PHASE1)
- Use of Nanotechnology Structured Water for the Prevention of Recurrent Stone Formation (NA)
- Treatment of Meniere's Disease With Migraine Medications (PHASE4)
- A Study of Losartan Compared to Losartan/HCTZ in Pediatric Patients With Hypertension (0954A-327) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Hydrochlorothiazide CI brief — competitive landscape report
- Placebo for Hydrochlorothiazide updates RSS · CI watch RSS
- IlDong Pharmaceutical Co Ltd portfolio CI